Ajanta Pharma Limited (AJANTPHARM.NS)
INR 2441.7
(2.83%)
INR 2441.7
(2.83%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 46.38 Billion INR | -0.87% |
| 2022 | 46.79 Billion INR | 15.37% |
| 2021 | 40.55 Billion INR | 7.33% |
| 2020 | 37.78 Billion INR | 13.86% |
| 2019 | 33.18 Billion INR | 23.09% |
| 2018 | 26.96 Billion INR | 10.11% |
| 2017 | 24.48 Billion INR | 34.34% |
| 2016 | 18.22 Billion INR | 23.04% |
| 2015 | 14.81 Billion INR | 29.23% |
| 2014 | 11.46 Billion INR | 20.75% |
| 2013 | 9.49 Billion INR | 32.18% |
| 2012 | 7.18 Billion INR | 10.7% |
| 2011 | 6.48 Billion INR | 24.25% |
| 2010 | 5.22 Billion INR | 5.47% |
| 2009 | 4.95 Billion INR | 6.96% |
| 2008 | 4.62 Billion INR | 28.61% |
| 2007 | 3.59 Billion INR | 34.15% |
| 2006 | 2.68 Billion INR | 11.41% |
| 2005 | 2.4 Billion INR | 11.02% |
| 2004 | 2.16 Billion INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2024 Q2 | 47.9 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 46.38 Billion INR | 0.0% |
| 2023 FY | 46.38 Billion INR | -0.87% |
| 2023 Q2 | 44.33 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 44.47 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 46.79 Billion INR | 15.37% |
| 2022 Q4 | 46.79 Billion INR | 0.0% |
| 2021 Q4 | 40.55 Billion INR | 0.0% |
| 2021 FY | 40.55 Billion INR | 7.33% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 40.63 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 37.78 Billion INR | 13.86% |
| 2020 Q4 | 37.78 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 36.7 Billion INR | 0.0% |
| 2019 Q4 | 33.18 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 30.95 Billion INR | 0.0% |
| 2019 FY | 33.18 Billion INR | 23.09% |
| 2019 Q3 | - INR | -100.0% |
| 2018 FY | 26.96 Billion INR | 10.11% |
| 2018 Q4 | 26.96 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 27.28 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 24.48 Billion INR | 34.34% |
| 2017 Q4 | 24.48 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 21.34 Billion INR | 0.0% |
| 2016 Q4 | 18.22 Billion INR | 0.0% |
| 2016 FY | 18.22 Billion INR | 23.04% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 17.3 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q4 | 14.81 Billion INR | 0.0% |
| 2015 FY | 14.81 Billion INR | 29.23% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 13.1 Billion INR | 0.0% |
| 2014 FY | 11.46 Billion INR | 20.75% |
| 2014 Q4 | 11.46 Billion INR | 0.0% |
| 2014 Q1 | - INR | 0.0% |
| 2013 FY | 9.49 Billion INR | 32.18% |
| 2012 FY | 7.18 Billion INR | 10.7% |
| 2011 FY | 6.48 Billion INR | 24.25% |
| 2010 FY | 5.22 Billion INR | 5.47% |
| 2009 FY | 4.95 Billion INR | 6.96% |
| 2008 FY | 4.62 Billion INR | 28.61% |
| 2007 FY | 3.59 Billion INR | 34.15% |
| 2006 FY | 2.68 Billion INR | 11.41% |
| 2005 FY | 2.4 Billion INR | 11.02% |
| 2004 FY | 2.16 Billion INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Aarti Drugs Limited | 24.32 Billion INR | -90.695% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | -79.636% |
| Albert David Limited | 4.97 Billion INR | -831.42% |
| Alembic Limited | 23.28 Billion INR | -99.178% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -9751.58% |
| Hester Biosciences Limited | 6.62 Billion INR | -600.296% |
| Hikal Limited | 24.87 Billion INR | -86.495% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | -298.109% |
| Ind-Swift Limited | 6.54 Billion INR | -608.723% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | -106.665% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -1832.167% |
| Lincoln Pharmaceuticals Limited | 7 Billion INR | -562.352% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | -1291.138% |
| Medico Remedies Limited | 961.95 Million INR | -4721.847% |
| Morepen Laboratories Limited | 12.93 Billion INR | -258.674% |
| Procter & Gamble Health Limited | 7.94 Billion INR | -483.915% |
| RPG Life Sciences Limited | 5.12 Billion INR | -804.399% |
| Sigachi Industries Limited | 6.94 Billion INR | -568.205% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 94.573% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | -105.777% |
| Themis Medicare Limited | 5.66 Billion INR | -718.901% |
| Unichem Laboratories Limited | 31.69 Billion INR | -46.352% |
| Vaishali Pharma Limited | 799.55 Million INR | -5701.2% |
| Venus Remedies Limited | 6.26 Billion INR | -639.976% |
| Windlas Biotech Limited | 6.26 Billion INR | -640.713% |
| ZIM Laboratories Limited | 4.46 Billion INR | -938.084% |
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | 28.038% |
| Bafna Pharmaceuticals Limited | 1.47 Billion INR | -3040.804% |
| FDC Limited | 24.68 Billion INR | -87.934% |
| Gufic Biosciences Limited | 10.92 Billion INR | -324.55% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 59.836% |
| Nectar Lifesciences Limited | 21.91 Billion INR | -111.697% |
| Orchid Pharma Limited | 15.53 Billion INR | -198.505% |
| Alkem Laboratories Limited | 155.74 Billion INR | 70.219% |
| Bajaj HealthCare Limited | 7.65 Billion INR | -506.224% |
| Brooks Laboratories Limited | 904.45 Million INR | -5028.387% |
| Eris Lifesciences Limited | 70.48 Billion INR | 34.196% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | -62.727% |
| Solara Active Pharma Sciences Limited | 23.46 Billion INR | -97.664% |
| Innova Captab Limited | 13.2 Billion INR | -251.159% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -2036.739% |
| Wanbury Limited | 3.43 Billion INR | -1250.359% |
| Lupin Limited | 239.97 Billion INR | 80.671% |
| Sakar Healthcare Limited | 3.88 Billion INR | -1093.434% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 89.709% |
| Divi's Laboratories Limited | 154.7 Billion INR | 70.017% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | -330.266% |
| Mankind Pharma Limited | 119.63 Billion INR | 61.228% |
| Sequent Scientific Limited | 15.4 Billion INR | -201.119% |
| Laurus Labs Limited | 83.87 Billion INR | 44.696% |
| Neuland Laboratories Limited | 18.32 Billion INR | -153.11% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | -16.13% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 67.696% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 84.159% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | -1164.312% |
| Wockhardt Limited | 76.49 Billion INR | 39.36% |
| Bal Pharma Limited | 3.2 Billion INR | -1347.737% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 88.031% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | -282.116% |
| Par Drugs and Chemicals Limited | 1.01 Billion INR | -4464.846% |
| Caplin Point Laboratories Limited | 26.97 Billion INR | -71.959% |
| Shilpa Medicare Limited | 30.93 Billion INR | -49.954% |
| Valiant Laboratories Limited | 3.42 Billion INR | -1253.534% |
| Aarey Drugs & Pharmaceuticals Limited | 3.04 Billion INR | -1420.823% |
| Granules India Limited | 55.2 Billion INR | 15.986% |
| Medicamen Biotech Limited | 2.94 Billion INR | -1474.885% |
| Ipca Laboratories Limited | 111.01 Billion INR | 58.218% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | -1046.233% |
| Piramal Enterprises Limited | 826.05 Billion INR | 94.385% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 69.203% |
| NATCO Pharma Limited | 69.06 Billion INR | 32.838% |
| Suven Life Sciences Limited | 2.84 Billion INR | -1528.061% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -2503.282% |
| Strides Pharma Science Limited | 58.39 Billion INR | 20.572% |
| Indoco Remedies Limited | 21.44 Billion INR | -116.269% |
| Alpa Laboratories Limited | 1.82 Billion INR | -2439.89% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -2974.455% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | -800.588% |